Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1974 5
1975 4
1976 4
1977 2
1978 2
1981 1
1983 3
1984 1
1985 3
1986 2
1987 3
1988 1
1990 1
1991 1
1992 4
1994 1
1995 2
1996 6
1997 6
1998 5
1999 2
2000 4
2001 3
2002 3
2005 1
2007 1
2008 1
2010 2
2011 1
2012 2
2013 4
2014 4
2015 2
2016 1
2017 1
2018 2
2019 4
2020 9
2021 8
2022 8
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Results by year

Filters applied: . Clear all
Page 1
Epigenetics: a landscape takes shape.
Goldberg AD, Allis CD, Bernstein E. Goldberg AD, et al. Cell. 2007 Feb 23;128(4):635-8. doi: 10.1016/j.cell.2007.02.006. Cell. 2007. PMID: 17320500 Free article. Review.
Single-cell mutation analysis of clonal evolution in myeloid malignancies.
Miles LA, Bowman RL, Merlinsky TR, Csete IS, Ooi AT, Durruthy-Durruthy R, Bowman M, Famulare C, Patel MA, Mendez P, Ainali C, Demaree B, Delley CL, Abate AR, Manivannan M, Sahu S, Goldberg AD, Bolton KL, Zehir A, Rampal R, Carroll MP, Meyer SE, Viny AD, Levine RL. Miles LA, et al. Among authors: goldberg ad. Nature. 2020 Nov;587(7834):477-482. doi: 10.1038/s41586-020-2864-x. Epub 2020 Oct 28. Nature. 2020. PMID: 33116311 Free PMC article.
Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia.
Xiao W, Chan A, Waarts MR, Mishra T, Liu Y, Cai SF, Yao J, Gao Q, Bowman RL, Koche RP, Csete IS, DelGaudio NL, Derkach A, Baik J, Yanis S, Famulare CA, Patel M, Arcila ME, Stahl M, Rampal RK, Tallman MS, Zhang Y, Dogan A, Goldberg AD, Roshal M, Levine RL. Xiao W, et al. Among authors: goldberg ad. Blood. 2021 Mar 11;137(10):1377-1391. doi: 10.1182/blood.2020007897. Blood. 2021. PMID: 32871587 Free PMC article.
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML.
Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, King AC, Daniyan AF, Famulare C, Cuello BM, Horvat TZ, Abdel-Wahab O, Levine RL, Viny AD, Stein EM, Cai SF, Roshal M, Tallman MS, Goldberg AD. Stahl M, et al. Among authors: goldberg ad. Blood Adv. 2021 Mar 9;5(5):1552-1564. doi: 10.1182/bloodadvances.2020003734. Blood Adv. 2021. PMID: 33687434 Free PMC article.
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia.
McCarter JGW, Nemirovsky D, Famulare CA, Farnoud N, Mohanty AS, Stone-Molloy ZS, Chervin J, Ball BJ, Epstein-Peterson ZD, Arcila ME, Stonestrom AJ, Dunbar A, Cai SF, Glass JL, Geyer MB, Rampal RK, Berman E, Abdel-Wahab OI, Stein EM, Tallman MS, Levine RL, Goldberg AD, Papaemmanuil E, Zhang Y, Roshal M, Derkach A, Xiao W. McCarter JGW, et al. Among authors: goldberg ad. Blood Adv. 2023 Sep 12;7(17):5000-5013. doi: 10.1182/bloodadvances.2023009675. Blood Adv. 2023. PMID: 37142255 Free PMC article.
Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
Badar T, Atallah E, Shallis R, Saliba AN, Patel A, Bewersdorf JP, Grenet J, Stahl M, Duvall A, Burkart M, Palmisiano N, Bradshaw D, Kubiak M, Dinner S, Goldberg AD, Abaza Y, Murthy GSG, Kota V, Litzow MR. Badar T, et al. Among authors: goldberg ad. Leukemia. 2023 Apr;37(4):799-806. doi: 10.1038/s41375-023-01847-7. Epub 2023 Feb 18. Leukemia. 2023. PMID: 36807649
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study.
Garcia-Manero G, Goldberg AD, Winer ES, Altman JK, Fathi AT, Odenike O, Roboz GJ, Sweet K, Miller C, Wennborg A, Hickman DK, Kanagal-Shamanna R, Kantarjian H, Lancet J, Komrokji R, Attar EC, Sallman DA. Garcia-Manero G, et al. Among authors: goldberg ad. Lancet Haematol. 2023 Apr;10(4):e272-e283. doi: 10.1016/S2352-3026(22)00403-3. Lancet Haematol. 2023. PMID: 36990622 Clinical Trial.
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
Shimony S, Bewersdorf JP, Shallis RM, Liu Y, Schaefer EJ, Zeidan AM, Goldberg AD, Stein EM, Marcucci G, Lindsley RC, Chen EC, Ramos Perez J, Stein A, DeAngelo DJ, Neuberg DS, Stone RM, Ball B, Stahl M. Shimony S, et al. Among authors: goldberg ad. Leukemia. 2024 Apr;38(4):762-768. doi: 10.1038/s41375-024-02175-0. Epub 2024 Feb 20. Leukemia. 2024. PMID: 38378841
Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.
Stahl M, Derkach A, Farnoud N, Bewersdorf JP, Robinson T, Famulare C, Cho C, Devlin S, Menghrajani K, Patel MA, Cai SF, Miles LA, Bowman RL, Geyer MB, Dunbar A, Epstein-Peterson ZD, McGovern E, Schulman J, Glass JL, Taylor J, Viny AD, Stein EM, Getta B, Arcila ME, Gao Q, Barker J, Shaffer BC, Papadopoulos EB, Gyurkocza B, Perales MA, Abdel-Wahab O, Levine RL, Giralt SA, Zhang Y, Xiao W, Pai N, Papaemmanuil E, Tallman MS, Roshal M, Goldberg AD. Stahl M, et al. Among authors: goldberg ad. Am J Hematol. 2023 Jan;98(1):79-89. doi: 10.1002/ajh.26757. Epub 2022 Oct 31. Am J Hematol. 2023. PMID: 36251406 Free PMC article.
125 results